Ritter Pharmaceuticals (NASDAQ:RTTR) reports that the last participant in its Phase 3 Liberatus study evaluating RP-G28 for the treatment of lactose intolerance has completed the final visit.
Topline data should be available in Q4.
Shares were up 6% premarket on average volume.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.